1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate the efficacy and safety of combinations of empagliflozin/linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.

          Related collections

          Author and article information

          Journal
          Diabetes Care
          Diabetes care
          1935-5548
          0149-5992
          Mar 2015
          : 38
          : 3
          Affiliations
          [1 ] University of Texas Health Science Center, San Antonio, TX defronzo@uthscsa.edu.
          [2 ] National Research Institute, Los Angeles, CA.
          [3 ] Boehringer Ingelheim, Ltd., Bracknell, Berkshire, U.K.
          [4 ] Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
          [5 ] Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
          Article
          dc14-2364
          10.2337/dc14-2364
          25583754
          © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

          Comments

          Comment on this article